Angiogenesis

2-Methoxyestradiol Pre-Clinical Studies Published

Published in Cancer Weekly, February 3rd, 1997

EntreMed Inc., Rockville, Maryland, announced that it licensed worldwide rights to 2-Methoxyestradiol (2-ME), an inhibitor of breast cancer and angiogenesis.

2-ME, a natural estrogen metabolite, was discovered by Dr. Robert D'Amato and colleagues at Children's Hospital, Boston, Massachusetts, to inhibit the growth of breast cancer cells and to block angiogenesis.

In collaborative pre-clinical trials with the U.S. National Cancer Institute (NCI), Bethesda, Maryland, it was shown that 2-ME acts similarly to Taxol, inhibiting cellular machinery involved in replicating cancer cells. 2-ME also is an anti-angiogenic agent that prevents the growth of new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry